Compare · BJDX vs RMD
BJDX vs RMD
Side-by-side comparison of Bluejay Diagnostics Inc. (BJDX) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BJDX and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $27.04B, about 12044.7x BJDX ($2.2M).
- BJDX has been more active in the news (6 items in the past 4 weeks vs 5 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 1 for BJDX).
- Company
- Bluejay Diagnostics Inc.
- ResMed Inc.
- Price
- $2.17+2.36%
- $186.48-2.17%
- Market cap
- $2.2M
- $27.04B
- 1M return
- +21.23%
- -
- 1Y return
- -70.19%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 5
- Recent ratings
- 1
- 25
Bluejay Diagnostics Inc.
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest BJDX
- Director Wurth Douglas Clark bought $25,000 worth of shares (12,500 units at $2.00) (SEC Form 4)
- President and CEO Dey Indranil bought $25,000 worth of shares (12,500 units at $2.00), increasing direct ownership by 56,818% to 12,522 units (SEC Form 4)
- Director Chase Donald R bought $25,000 worth of shares (12,500 units at $2.00), increasing direct ownership by 50,000% to 12,525 units (SEC Form 4)
- Director Zeidman Fred S bought $25,000 worth of shares (12,500 units at $2.00) (SEC Form 4)
- Director Dey Svetlana bought $25,000 worth of shares (12,500 units at $2.00), increasing direct ownership by 1,250,000% to 12,501 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Bluejay Diagnostics Inc.
- SEC Form 10-Q filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
- SEC Form DEF 14A filed by Bluejay Diagnostics Inc.
Latest RMD
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.
- Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition